Schizophrenia and diabetes mellitus: Diabetes mellitus or metabolic syndrome caused by new generation antipsychotics;Şizofreni ve diyabet: Yeni kuşak antipsikotiklerin yol açtiǧi diyabet veya metabolik sendrom

Klinik Psikofarmakoloji Bulteni

Volumn 17, Issue 4, 2007, Pages 207-216

  Usta, Evrim ^a   Metin, Özmen ^a   Birsöz, Sunar ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Antipsychotics; Diabetes mellitus; Metabolic syndrome; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA;

EID: 38049054269     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Sadock BJ, Sadock VA. Endocrine and Metabolic Disorders, Diabetes Mellitus, Kaplan and Sadock's Comprehensive Textbook of Psychiatry, Eighth edition, Volume two, 2004; 2161-2162
2. Charbonnel B. What a psychiatrist needs to know about diabetes, Eur Psychiatry, 2005; 20: 330-334
3. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB,Chakos M, Lieberman JA.. Changes in glucose and cholesterol levels inpatients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-296
4. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL.. Diabetes mellitus in schizophrenic patients. Comp Psychiatry 1996; 37: 68-73
5. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A.. Prevelance on correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903-912
6. F Casadebaig , A Philippe, J.M. Guillaud-Bataille, M.F. Gausset, N Quemada and J.L. Terra. Schizophrenic patients: physical health and access to somatic care. Eur Psychiatry 1997; 12: 289-293
7. Subramaniam M, Chong SA, Pek E.. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry2003; 48: 345-347
8. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerancein first-episode, drug-naive patients with schizophrenia. Am JPsychiatry 2003; 160(2): 284-289
9. Thomas P, Raymondet P, Charbonnel B, Vaiva G. Are the specific care requirements for patients with schizoprenia and diabetes or with a risk of diabetes? Eur Psychiatry 2005; 20: 358-363
10. Rouillon F, Sorbara F. Schizoprenia and diabetes: epidemiological data, Eur Psychiatry 2005; 20: 345-348
11. Bellivier F. Schizoprenia, antipsychotics and diabetes: genetic aspects, Eur Psychiatry 2005; 20: 335-339
12. Che_a D, Dumitrescu C, Georgescu M, Cocioab_ G, Lichiardopol R, Stamoran M,Ionescu-Tîrgovişte C, P_unescu-Georgescu M, Mincu I.. A study on the types of diabetes mellitus in firstdegree relatives of diabetic patients. Diabete Metab 1990; 16: 11-15
13. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. İncrease prevalence type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorder independent of psychotropic drug use. J Affect Disord 2002; 70: 19-26
14. McGuffin P, Tandon K, Corsico A. Lincage and association studies of schizoprenia. Curr Psychiatry Rep 2003; 121-127
15. Wolford JK, Gruber JD, Ossowski VM, Vozarova B, Antonio Tataranni P, Bogardus C,Hanson RL.. A C-reactive protein promoter polymorphisms associated with type 2 diabetes mellitus in Pima İndians. Mol Genet Metab 2003; 78: 136-144
16. Wolford JK, Konheim YL, Colligan PB, Bogardus C.Association of a F479L variant in the cytosolic phospholipase A2 gene (PLA2G4A) with decreased glucose turnover and oxidation rates in Pima Indians. Mol Genet Metab 2003; 79: 61-66
17. Hager J, Dina C, Francke S, Dubois S, Houari M, Vatin V, Vaillant E, Lorentz N,Basdevant A, Clement K, Guy-Grand B, Froguel P.. A genomewide sean for human obesity genes reveals a major susceptibility locus on chromosome 10. Nat Genet 1998; 20: 304-308
18. Mitchell BD, Cole SA, Hsueh WC, Comuzzie AG, Blangero J, MacCluer JW, Hixson JE.Linkage of serum insulin concentrations to chromosome 3p in Mexican Americans. Diabetes 2000; 49: 513-516
19. Collier DA, Barrett TG, Curtis D, Macleod A, Arranz MJ, Maassen JA, Bundey S.Linkage of Wolfram syndrome to chromosome 4p16.1 and evidence for heterogeneity. Am J Hum Genet 1996; 59: 855-863
20. Blasi C, Pierelli F, Rispoli E, Saponara M, Vingolo E, Andreani D. Wolfram's syndrome: a clinical, diagnostic, and interpretativecontribution. Diabetes Care 1986; 9: 521-528
21. Inoue H, Tanizawa Y, Wasson J, Behn P, Kalidas K, Bernal-Mizrachi E, Mueckler M,Marshall H, Donis-Keller H, Crock P, Rogers D, Mikuni M, Kumashiro H, Higashi K,Sobue G, Oka Y, Permutt MA. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 1998; 20: 143-148
22. Evans KL, Lawson D, Meitinger T, Blackwood DH, Porteous DJ.. Mutational analysis of the Wolfram syndrome gene in two families with chromosome 4p-linked bipolar affective disorder. Am J Med Genet 2000; 96: 158-160
23. Torres R, Leroy E, Hu X, Katrivanou A, Gourzis P, Papachatzopoulou A, Athanassiadou A, Beratis S, Collier D, Polymeropoulos MH.Mutation screening of the Wolfram sendrome gene in psychiatric patients. Mol Psychiatry 2001; 6: 39-43
24. Eubanks JH, Altherr M, Wagner-McPherson C, McPherson JD, Wasmuth JJ, Evans GA.Localization of the D5 dopamine receptor gene to human chromosome 4pI5.1-pI5.3, centromeric to the Huntington' s disease locus. Genomics 1992; 12: 510-516
25. Chiba M, Suzuki S, Hinokio Y, Hirai M, Satoh Y, Tashiro A, Utsumi A, Awata T,Hongo M, Toyota T.Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metabolism 2000; 49: 1145-1149
26. Sten-Linder M, Wedell A, Iselius L, Efendic S, Luft R, Luthman H.DNA polymorphisms in the human tyrosine hydroxylase/insülin/insülin-like growth factor II chromosomal region in relation to glucose and insülin responses. Diabetologia 1993; 36: 25-32
27. Tejedor-Real P, Faucon Biguet N, Dumas S, Mallet J.Tyrosine hydroxylase mRNA and proteinare down-regulated by chronic clozapine in both the mesocorticolimbic and the nigrostritial systems. J Neurosci Res 2003; 72: 105-115
28. Kaneda Y, Fujii A, Ohmori T. The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(5): 935-938
29. Andrews RCR. Diabetes and schizophrenia: genes or zinc deficiency. Lancet 1992; 340: 1160
30. Ryan MCM, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002; 71: 239-257
31. Sneed KB, Gonzalez EC. Type 2 Diabetes mellitus induced by an atypical antipsychotic medication, JABFP May-June 2003; 16: 251
32. Gianfrancesco F, White R, Wang RH, Nasrallah HA.Antipsychotic-induced type 2 diabetes: Evidence from a large health plan database, J Clin Psychoparmacol, August 2003; 23: 328-329
33. Goudie AJ, Halford JC, Dovey TM, Cooper GD, Neill JC.H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 2209
34. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P,Jayathilake K, Meltzer HY, Roth BL.H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-526
35. Tecott LH., LM Sun, SF Akana, AM Strack, DH Lowenstein. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374: 542-546
36. T. Fujisawa H. Ikegami, E. Yamato K. Takekawa, Y. Nakagawa, Y. Hamada T. Oga1, H. Ueda, M. Shintani, M. Fukuda and T. Ogihara. Association of Trp64Arg mutation of the beta3-adrenergic-receptor with NIDDM and body weight gain. Diabetologia 1996; 39: 349-352
37. Shayegan DK, Stahl SM. Atypical antipsychotics:matching reseptor profile to individual patient's clinical profile. CNS Spectr 2004; 9: 6-14
38. Brömel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg JC, Hebebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998; 3: 76-80
39. Hägg S, Söderberg S, Ahrén B, Olsson T, Mjörndal T.Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 2001; 62: 843-848.
40. Pijl H. Reduced dopaminergic tone in hypothalamic neural circuits: expression of a "thrifty" genotype underlying the metabolic syndrome? Eur J Pharmacol, 7 November 2003; 480: 125-131
41. Birkás Kováts D, Palik E, Faludi G, Cseh K.Possible connection between ghrelin, resistin and TNF - alpha levels and metabolic syndrome caused by atypical antipsychotics. Neuropsychopharmacologia Hungarica, Sep 2005; 7: 132-139
42. Jin H, Meyer JM, Jeste DV.Atypical antipsychotics and glucose dysregulation: asystematic review, Schizophr Res, 2004; 1-18
43. International Diabetes Federation Metobolic Syndrome Conconsus, Berlin 2005.
44. Expert Panel. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497
45. K Altinbaş, E Kurt, ET Oral. İkinci kuşak antipsikotiklerin endokrin yan etkileri: İstisna mi, kural mi?, Anadolu Psikiyatri Dergisi, 2005; 6: 259-266
46. Newcomer JW, Nasrallah HA, Loebel AD.The atypical therapy and metabolic issues and national survey: practice patterns and kowledge of psychiatrists. J Clin Psychophar-macol. 2004; 24(suppl 1): 1-6
47. Schatzberg AF, Nemeroff CB. Treatment of schizophrenia, weight gain, diabetes, and hiperlipidemia, Textbook of Psychopharmacology, The American Psychiatric Publishing, Third Edition, 2004; 897-898
48. Hedenmalm K, Hägg S, Ståhl M, Mortimer O, Spigset O.Glucose intolerance with atypical antipsychotics. Drug safety, 2002; 25: 1107-1116
49. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC.The effects of novel antipsychotics on glucose and lipid levels, J. Clin Psychiatry, 2002; 63: 856-865
50. Jin H, Meyer JM, Jeste DV.Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry, 2002; 14: 59-64
51. A. E. Danaci, S. Mizrak, Z. Hekimsoy, İ. İçelli. Olanzapin'e baǧli diabetes mellitus: Bir olgu sunumu. Klinik Psikofarmakoloji Bülteni, 2003; 13: 94-96
52. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differantial effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry, 2002; 63: 920-930
53. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, KeefeRS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical AntipsychoticTrials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N Engl J Med, 2005; 353: 1209-1223
54. Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D.Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin. Ther. 2003; 25: 1150-1171
55. Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC.Hiperglycemia and Diabetes in Patients with Schizophrenia or Schizoaffective Disorders, Diabetes Care, 2006; 29: 786
56. Reddymasu S, Bahta E, Levine S, Manas K, Slay LE.Elevated lipase and diabetic ketoacidosis associated with aripiprazole, JOP. 2006; 7: 303-305
57. Church CO, Stevens DL, Fugate SE.Diabetic ketoacidosis associated with aripiprazole, Diabet Med. 2005; 22: 1440-1443
58. Sertöz ÖÖ, Mete HE. Obezite tedavisinde bilişsel davranişçi grup terapisinin kilo verme, yaşam kalitesi ve psikopatolojiye etkileri: sekiz haftalik izlem çalişmas>. Klinik Psikofarmakoloji Bülteni, 2005; 15: 119-126